JP2005513419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005513419A5 JP2005513419A5 JP2003541863A JP2003541863A JP2005513419A5 JP 2005513419 A5 JP2005513419 A5 JP 2005513419A5 JP 2003541863 A JP2003541863 A JP 2003541863A JP 2003541863 A JP2003541863 A JP 2003541863A JP 2005513419 A5 JP2005513419 A5 JP 2005513419A5
- Authority
- JP
- Japan
- Prior art keywords
- pth
- pharmaceutical composition
- level
- agonist
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003982 Parathyroid hormone Human genes 0.000 claims 60
- 108090000445 Parathyroid hormone Proteins 0.000 claims 60
- 239000000199 parathyroid hormone Substances 0.000 claims 60
- 229960001319 parathyroid hormone Drugs 0.000 claims 60
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- 239000005557 antagonist Substances 0.000 claims 25
- 239000000556 agonist Substances 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 15
- 229940124597 therapeutic agent Drugs 0.000 claims 15
- 229930003316 Vitamin D Natural products 0.000 claims 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 9
- 235000019166 vitamin D Nutrition 0.000 claims 9
- 239000011710 vitamin D Substances 0.000 claims 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 9
- 229940046008 vitamin d Drugs 0.000 claims 9
- 238000012544 monitoring process Methods 0.000 claims 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 6
- 229910052791 calcium Inorganic materials 0.000 claims 6
- 239000011575 calcium Substances 0.000 claims 6
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims 4
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims 4
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 4
- 208000005475 Vascular calcification Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000058004 human PTH Human genes 0.000 claims 4
- DTXXSJZBSTYZKE-ZDQKKZTESA-N Maxacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](OCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C DTXXSJZBSTYZKE-ZDQKKZTESA-N 0.000 claims 3
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims 3
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims 3
- 229960002535 alfacalcidol Drugs 0.000 claims 3
- 238000007470 bone biopsy Methods 0.000 claims 3
- -1 calciferdiol Chemical compound 0.000 claims 3
- 229960005084 calcitriol Drugs 0.000 claims 3
- 235000020964 calcitriol Nutrition 0.000 claims 3
- 239000011612 calcitriol Substances 0.000 claims 3
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 3
- 229960002061 ergocalciferol Drugs 0.000 claims 3
- 229950006319 maxacalcitol Drugs 0.000 claims 3
- 230000001629 suppression Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 235000001892 vitamin D2 Nutrition 0.000 claims 3
- 239000011653 vitamin D2 Substances 0.000 claims 3
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/002,818 US6524788B1 (en) | 2001-11-02 | 2001-11-02 | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| US10/286,465 US7056655B2 (en) | 2001-11-02 | 2002-11-01 | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| PCT/US2002/035516 WO2003039572A1 (en) | 2001-11-02 | 2002-11-04 | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005513419A JP2005513419A (ja) | 2005-05-12 |
| JP2005513419A5 true JP2005513419A5 (enExample) | 2006-01-12 |
Family
ID=26670921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003541863A Pending JP2005513419A (ja) | 2001-11-02 | 2002-11-04 | 続発性上皮小体機能亢進症を有する腎性患者における上皮小体ホルモンの治療的抑制をモニタリングおよび誘導するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7056655B2 (enExample) |
| EP (1) | EP1448217A4 (enExample) |
| JP (1) | JP2005513419A (enExample) |
| CA (1) | CA2465862A1 (enExample) |
| WO (1) | WO2003039572A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820393B2 (en) * | 1999-01-14 | 2010-10-26 | Scantibodies Laboratory, Inc. | Methods, kits and antibodies for detecting parathyroid hormone |
| US6689566B1 (en) | 1999-01-14 | 2004-02-10 | Scantibodies Laboratory, Inc. | Methods, kits, and antibodies for detecting parathyroid hormone |
| US6838264B2 (en) * | 2000-12-05 | 2005-01-04 | Immutopics, Inc. | Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84 |
| EP1945185B1 (en) * | 2005-10-12 | 2016-02-03 | Proventiv Therapeutics, LLC | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
| SI1993559T1 (sl) | 2006-02-03 | 2017-01-31 | Opko Renal, Llc | Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3 |
| DK3357496T3 (da) | 2006-06-21 | 2020-05-11 | Opko Ireland Global Holdings Ltd | Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel |
| CA2684778C (en) | 2007-04-25 | 2017-09-05 | Cytochroma Inc. | Methods and compounds for vitamin d therapy |
| PT2148684E (pt) | 2007-04-25 | 2013-04-19 | Cytochroma Inc | Método de tratamento para a insuficiência e deficiência de vitamina d |
| ES3047207T3 (en) | 2007-04-25 | 2025-12-03 | Opko Renal Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| PT2148661E (pt) | 2007-04-25 | 2013-03-06 | Proventiv Therapeutics Llc | Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso |
| CN106853250A (zh) | 2008-04-02 | 2017-06-16 | 赛特克罗公司 | 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒 |
| US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| WO2017182237A1 (en) | 2016-03-28 | 2017-10-26 | Opko Ireland Global Holdings, Limited | Methods of vitamin d treatment |
| CN108445237A (zh) * | 2018-06-20 | 2018-08-24 | 广州市康润生物科技有限公司 | 一种pth快速免疫检测系统的新用途 |
| CN112349362B (zh) * | 2019-08-08 | 2025-06-20 | 深圳先进技术研究院 | 一种甲状旁腺激素分泌监测与调控系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369138A (en) * | 1980-07-15 | 1983-01-18 | Immuno Nuclear Corporation | Parathyroid radioimmunoassay |
| US4423037A (en) * | 1982-05-13 | 1983-12-27 | The General Hospital Corporation | Inhibitors of peptide hormone action |
| US4508828A (en) * | 1983-03-21 | 1985-04-02 | Immuno Nuclear Corporation | Bioassay of parathyroid hormone |
| FR2550204B1 (fr) * | 1983-08-05 | 1987-11-13 | Toyo Jozo Kk | Derives peptidiques de (nle8,nle1b, tyr34)-h-pth |
| DE3347548A1 (de) | 1983-12-30 | 1985-07-11 | Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch | Mittel und verfahren zur spezifischen immunologischen bestimmung des c-terminalen parathormonfragments 68-84 |
| DE3935738A1 (de) | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
| US5317010A (en) | 1991-10-10 | 1994-05-31 | Peter K. T. Pang | Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment |
| WO1994003201A1 (en) | 1992-08-05 | 1994-02-17 | Hilliker Sandra R | Parathyroid hormone fragments and analogs |
| DE4434551A1 (de) | 1994-09-28 | 1996-04-04 | Forssmann Wolf Georg Prof Dr D | Peptide aus der Sequenz des hPTH (1-37) |
| US6689566B1 (en) * | 1999-01-14 | 2004-02-10 | Scantibodies Laboratory, Inc. | Methods, kits, and antibodies for detecting parathyroid hormone |
| US6923968B2 (en) * | 2000-08-10 | 2005-08-02 | Scantibodies Laboratory, Inc. | Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis |
| US6524788B1 (en) * | 2001-11-02 | 2003-02-25 | Thomas L. Cantor | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
-
2002
- 2002-11-01 US US10/286,465 patent/US7056655B2/en not_active Expired - Fee Related
- 2002-11-04 EP EP02776462A patent/EP1448217A4/en not_active Withdrawn
- 2002-11-04 JP JP2003541863A patent/JP2005513419A/ja active Pending
- 2002-11-04 CA CA002465862A patent/CA2465862A1/en not_active Abandoned
- 2002-11-04 WO PCT/US2002/035516 patent/WO2003039572A1/en not_active Ceased
-
2006
- 2006-03-17 US US11/377,980 patent/US20060223119A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005513419A5 (enExample) | ||
| Cummings et al. | Denosumab for prevention of fractures in postmenopausal women with osteoporosis | |
| Horiuchi et al. | Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro | |
| Lane et al. | Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. | |
| AU2003207512B2 (en) | Treatment of bone disorders with skeletal anabolic drugs | |
| Henriksen et al. | Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2 | |
| Meunier et al. | The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis | |
| Body et al. | Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club | |
| JP7049412B2 (ja) | 骨折リスクの低減におけるＰＴＨｒＰアナログの使用 | |
| JP2018508489A (ja) | アルカリホスファターゼ欠損を有する被験者を治療する方法 | |
| JP2009508820A (ja) | 副甲状腺ホルモンアナログおよび使用法 | |
| NZ507056A (en) | Use of PTH in increasing bone toughness and stiffness and reducing fractures | |
| Pennisi et al. | Glucocorticoid-induced osteoporosis and its treatment | |
| JP2007518800A (ja) | Ｐｔｈ受容体アゴニストによる骨転移の治療 | |
| LERMAN et al. | Parathyroid hormone and the hypercalcemia of immobilization | |
| Nagasaki et al. | Invitro and invivo antagonists against parathyroid hormone-related protein | |
| Devogelaer et al. | Biologicals in osteoporosis: teriparatide and parathyroid hormone in women and men | |
| Cosman | Teriparatide and abaloparatide treatment for osteoporosis | |
| JP2008513459A (ja) | 骨同化物質を用いた骨疾患の治療方法 | |
| WO2018189674A1 (en) | Prevention of bone and mineral disorders by restoring calcium and phosphate homeostasis in patients suffering from chronic kidney disease. | |
| Oyoo et al. | Osteoperosis-from hormonal replacement therapy to bisphosphonates and beyond: a review | |
| Marsh et al. | Alternatives to HRT in prevention and treatment | |
| Ziólkowska | Minimizing bone abnormalities in children with renal failure | |
| Carranza et al. | Post-Transplant Osteoporosis | |
| Owens | Dose-Dependent Effects of Salmon Calcitonin on Bone Turnover in Ovariectomized Rats |